James Cassella, Ph.D.

James Cassella, Ph.D.

Chief Development OfficeratTrevi Therapeutics· In proxies 2023–2025

Pay in FY2025+14% from the year before · Trevi Therapeutics stock +203.9% the same year

James Cassella, Ph.D. was paid $1.6M in FY2025 (Dec), up 14%. Trevi Therapeutics stock rose 203.9% that year.

Pay$100 in the stock at the end of FY22 → $649
Pay is from the Summary Compensation Table of each Trevi Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Trevi TherapeuticsPublic company · 3 yr
    • Chief Development Officer2023 – Present · 3 yrStock in role +631%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?